OLMA - Olema Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

OLMA

OLEMA PHARMACEUTICALS, INC.

NASDAQ

$10.75

▲ UP 0.19% (0.02)

KEY STATISTICS

Market Cap$938.99 M

52w High$36.26

52w Low$6.35

Dividend Yield—

Frequency—

P/E-5.32

Volume505.26K

Shares Out.87.35M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Sean Bohen

COMPENSATION 2026

Salary$0

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$0

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 19, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

150

PRICE TARGET

Target High$38.00

Target Low$20.00

Target Median$35.00

Target Consensus$31.00

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$1.25M

NOV

MON

PRICE

$10.75 ▲ UP 0.19% (+$0.02)

About Olema Pharmaceuticals, Inc.

https://www.olema.com ↗

Olema Pharmaceuticals, a San Francisco-based clinical-stage biopharma founded in 2006, develops therapies for women's cancers, with lead candidate OP-1250 in Phase 1/2 trials for ER-positive breast cancer.

INDUSTRY

Biotechnology

A PRODUCT OLEMA PHARMACEUTICALS, INC. IS KNOWN FOR

Palazestrant (OP-1250)

Palazestrant, Olema Pharmaceuticals' lead oral ER antagonist and degrader for ER-positive, HER2-negative breast cancer, is in Phase 3 trials, has FDA Fast Track status, and aims to address a significant unmet medical need.